265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01164605 (ClinicalTrials.gov) | October 2010 | 14/7/2010 | Pilot Study of Raltegravir Lipodystrophy IISP | Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral Treatment | HIV Infection | Drug: Raltegravir | Southern California Institute for Research and Education | Merck Sharp & Dohme Corp. | Recruiting | N/A | N/A | Both | 30 | N/A | United States |
2 | NCT00656175 (ClinicalTrials.gov) | September 2008 | 2/4/2008 | Raltegravir Therapy for Women With HIV and Fat Accumulation | Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation | HIV Infections;Lipodystrophy | Drug: raltegravir | University of California, Los Angeles | Merck Sharp & Dohme Corp.;Case Western Reserve University;Vanderbilt University;Tufts University;University Health Network, Toronto | Completed | 18 Years | N/A | Female | 39 | Phase 2 | United States;Canada |